<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689284</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGAH22-05</org_study_id>
    <nct_id>NCT02689284</nct_id>
  </id_info>
  <brief_title>Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer</brief_title>
  <official_title>A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This main purpose of this clinical study is to learn about the safety and activity of
      margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and
      gastroesophageal junction cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: Both margetuximab and pembrolizumab are monoclonal antibodies used in
      combination to treat HER2+ gastric and gastroesophageal junction cancer. This study has two
      parts: Dose Escalation and Dose Expansion. The Dose Escalation phase of the study will
      evaluate safety of escalating doses of the combination treatment. The Dose Expansion phase
      will evaluate safety and activity of the combination once the final dose and schedule are
      defined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the recommended expansion phase dose of margetuximab in combination with pembrolizumab</measure>
    <time_frame>9 months</time_frame>
    <description>Characterize maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of margetuximab when administered in combination with pembrolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Tumor Activity</measure>
    <time_frame>12 months</time_frame>
    <description>Investigate the preliminary anti-tumor activity as measured by response duration of margetuximab when administered in combination with pembrolizumab, using both conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related response criteria (irRC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Tumor Activity</measure>
    <time_frame>12 Months</time_frame>
    <description>Investigate the preliminary anti-tumor activity, as measured by objective response rate (ORR) of margetuximab when administered in combination with pembrolizumab, using conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related response criteria (irRC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 Months</time_frame>
    <description>To investigate the preliminary effect of the combination treatment on OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
    <description>To investigate the preliminary effect of the combination treatment on PFS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Stomach Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the MTD or MAD (if no MTD is defined) of escalating doses of margetuximab administered in combination with pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine safety and activity of margetuximab and pembrolizumab combination dose (as determined from the Dose Escalation Phase)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>margetuximab in combination with pembrolizumab</intervention_name>
    <description>Combination treatment is administered once every 21-day cycle</description>
    <arm_group_label>Dose Escalation Phase</arm_group_label>
    <arm_group_label>Dose Expansion Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent.

          2. Age ≥ 18 years old.

          3. Unresectable locally advanced or metastatic histologically proven HER2+
             gastroesophageal junction (GEJ) or gastric adenocarcinoma.

          4. HER2+ as 3+ by IHC or in-situ hybridation (ISH) amplified.

          5. Have received prior treatment with trastuzumab.

          6. Have received treatment with at least one or more lines of cytotoxic chemotherapy in
             the metastatic setting.

          7. Resolution of chemotherapy, immunotherapy or radiation-related toxicities.

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          9. Life expectancy ≥ 12 weeks.

         10. Measurable disease as per RECIST 1.1 criteria.

         11. Archival or newly obtained tissue sample of a tumor lesion.

         12. Adequate organ function as determined by following laboratory parameters:

               1. Heme: Plt Ct ≥ 100 x 103/µL, ANC ≥ 1.5 x 103/µL, and Hemoglobin ≥ 9 g/dL

               2. Chemistry: ALT/AST ≤ 3.0 x ULN, TBili ≤1.5 x ULN, and Cr &lt; 2 mg/dL

         13. Female patients of childbearing potential must have a negative pregnancy test and
             agree to use two forms of acceptable contraceptive measures from the time of consent
             through 120 days after discontinuation of study drug administration.

         14. Male patients with partners of childbearing potential must use barrier contraception.

        Exclusion Criteria:

          1. Patients with symptomatic central nervous system (CNS) metastases.

          2. Patients with any history of known or suspected autoimmune disease with the specific
             exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic
             treatment.

          3. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.

          4. Treatment with any systemic anti-neoplastic therapy, or investigational therapy within
             the 3 weeks prior to the initiation of study drug.

          5. Treatment with radiation therapy within 3 weeks prior to the initiation of study drug
             administration.

          6. Treatment with corticosteroids (≥10 mg per day prednisone or equivalent) or other
             immune suppressive drugs within the 14 days prior to the initiation of study drug
             administration.

          7. History of clinically-significant cardiovascular disease.

          8. Clinically-significant pulmonary compromise, including a requirement for supplemental
             oxygen use to maintain adequate oxygenation.

          9. Presence of active pneumonitis

         10. Clinically-significant gastrointestinal disorders, such as perforation,
             gastrointestinal bleeding, or diverticulitis.

         11. Evidence of active viral, bacterial, or systemic fungal infection.

         12. Known positive testing for human immunodeficiency virus (HIV)or history of acquired
             immune deficiency syndrome (AIDS).

         13. Known history of or positive test for hepatitis B or hepatitis C infection.

         14. Second primary invasive malignancy that has not been in remission for greater than 2
             years.

         15. Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient
             contained in the drug or vehicle formulation for margetuximab or pembrolizumab.

         16. Female patient who is breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Davidson, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice Drumheller</last_name>
    <email>drumhellera@MacroGenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-200-4422</phone>
    </contact>
    <investigator>
      <last_name>Howard Hochster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University-Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sunnie Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Catenacci, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ronan Kelly, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute/Harvard University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter C Enzinger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter C Enzinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eunice Kwak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Miksad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eirini Pectasides, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip A Philip, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A. Craig Lockhart, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hope Uronis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Denlinger, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Crystal Denlinger, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johanna Bendell, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre - McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalyn Juergens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosalyn Juergens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Alcindor, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Alcindor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon-Koo Kang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yoon-Koo Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeul Hong Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yeul Hong Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Cheul Oh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sang Cheul Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Hoon Park, MD</last_name>
    </contact>
    <investigator>
      <last_name>Se Hoon Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun Wook Lee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Keun Wook Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yung Jue Bang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yung Jue Bang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Ng C.H, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthew C.H Ng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Cancer Institute</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Ean Chee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cheng Ean Chee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raffles Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Yew Hee Poon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Donald Yew Hee Poon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun-Huei Yeh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kun-Huei Yeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yee Chao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yee Chao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Liang Ho, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ching-Liang Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomach Cancer</keyword>
  <keyword>Gastroesophageal Junction</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Cancer of the Stomach</keyword>
  <keyword>Cancer of Stomach</keyword>
  <keyword>Stomach</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>HER2+</keyword>
  <keyword>GEJ</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Margetuximab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Human epidermal growth factor receptor 2</keyword>
  <keyword>Human epidermal growth factor receptor 2-positive</keyword>
  <keyword>gastroesophageal junction cancer</keyword>
  <keyword>Pembro</keyword>
  <keyword>PD-L1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD</keyword>
  <keyword>Tumor</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

